{"@context":"https:\/\/schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"A first-in-human, open label, phase I\/II study to evaluate the safety, anti-tumor activity, pharmacokinetics, and pharmacodynamics of SAR446523 monotherapy, an anti-GPRC5D ADCC-enhanced monoclonal antibody in dose escalation and dose optimization, and to evaluate the efficacy of SAR446523 in dose expansion, in participants with relapsed and refractory multiple myeloma.","item":"https:\/\/www.regionalcancercare.org\/trials\/a-first-in-human-open-label-phase-i-ii-study-to-evaluate-the-safety-anti-tumor-activity-pharmacokinetics-and-pharmacodynamics-of-sar446523-monotherapy-an-anti-gprc5d-adcc-enhanced-monoclonal-ant\/#breadcrumbitem"}]}